Predicting Olfactory Loss In Chronic Rhinosinusitis Using Machine Learning

Vijay R. Ramakrishnan, MD[1], Jaron Arbet, PhD[2], Jess C. Mace, MPH, CCRP[3], Stephanie Shintani Smith, MD, MS,[4] Zachary M. Soler, MD, MSc[5], Timothy L. Smith, MD, MPH[3]

Department of Otolaryngology-Head and Neck Surgery, University of Colorado, Aurora, CO.[1]

Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado-Denver Anschutz Medical Campus, Aurora, CO.[2]

Department of Otolaryngology-Head and Neck Surgery, Oregon Health Sciences University, Portland, OR.[3]

Department of Otolaryngology-Head and Neck Surgery, Northwestern University, Chicago, IL.[4]

Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, SC.[5]

Corresponding author:
Vijay R. Ramakrishnan, MD
Department of Otolaryngology, University of Colorado
12631 E 17th Ave, B205
Aurora, CO. 80045
Phone: 303-724-1965
Fax: 303-724-1961
E-mail: Vijay.Ramakrishnan@ucdenver.edu

Running Title: Machine Learning and CRS Olfactory Loss

Financial Disclosures: V.R.R., J.C.M., Z.M.S., T.L.S., and S.S.S. are supported by grants for this investigation from the National Institute on Deafness and Other Communication Disorders (NIDCD) and the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health, Bethesda, MD., USA [R01 DC005805 (T.L.S.), K23 DC014747 (V.R.R.), 1P01AI145818-01 (S.S.S.)]. Public clinical trial registration (www.clinicaltrials.gov) ID# NCT01332136. Contents are the authors' sole responsibility and do not necessarily represent official NIH views.

Conflicts of Interest: None related to this study

39   **ABSTRACT**

40   **Objective**
41   Compare machine learning (ML) based predictive analytics methods to traditional logistic
42   regression in classification of olfactory dysfunction in chronic rhinosinusitis (CRS-OD), and
43   identify predictors within a large multi-institutional cohort of refractory CRS patients.
44
45   **Methods**
46   Adult CRS patients enrolled in a prospective, multi-institutional, observational cohort study were
47   assessed for baseline CRS-OD using a smell identification test (SIT) or brief SIT (bSIT). Four
48   different ML methods were compared to traditional logistic regression for classification of CRS
49   normosmics versus CRS-OD.
50
Results
Data were collected for 611 study participants who met inclusion criteria between April 2011
and July 2015. 34% of enrolled patients demonstrated olfactory loss on psychophysical testing.
Differences between CRS normosmics and those with smell loss included objective disease
measures (CT and endoscopy scores), age, sex, prior surgeries, socioeconomic status, steroid use,
polyp presence, asthma, and aspirin sensitivity. Most ML methods outperformed traditional
logistic regression in terms of predictive ability. Top predictors include factors previously
reported in the literature, as well as several socioeconomic factors.
59
Conclusion
Olfactory dysfunction is a variable phenomenon in CRS patients. ML methods outperform
traditional logistic regression in classification of normosmia versus smell loss in CRS, and are
able to include numerous risk factors into prediction models. These results carry implications for
basic science and clinical research in hyposmia secondary to sinonasal disease, the most common
cause of persistent olfactory loss in the general population.
66

INTRODUCTION

Olfactory loss is common, affecting up to 25% of the adult population, with chronic rhinosinusitis (CRS) being a major cause of persistent olfactory loss [1]. Smell loss is a hallmark of CRS, particularly in those with nasal polyps, and is one of the cardinal diagnostic symptoms for the disease [2-4]. Curiously, this symptom does not affect all CRS patients. Just as CRS is a heterogeneous disease [5], previous literature has estimated a 20-80% prevalence of olfactory loss in CRS cohorts, based on the sensitivity of olfactory assessment used and the proportion of enrolled subjects with nasal polyps (CRSwNP). A recent study using well-defined CRS diagnostic criteria and Sniffin' Sticks objective testing showed a 44% prevalence of smell loss in CRSsNP subjects and 58% in CRSwNP [6]. Risk factors associated with CRS-OD identified in this study included disease severity score on computed tomography (CT) and the presence of comorbid conditions such as diabetes, allergy, and asthma. Adding a healthy control group for comparison, Schlosser et al. noted CRS-OD to affect CRSwNP patients more than CRSsNP, and identified age as an additional risk factor [7]. Given that most existing studies consist of single-institution cohorts, with subjects undergoing variable treatment regimens, and different assessments of smell function, a systematic review and meta-analysis was performed by Kohli et al. [8] to clarify the presence of OD in CRS and identify consistent risk factors. The authors included 47 studies in the analysis, and identified age, CT score, and presence of nasal polyps as the three most important risk factors for CRS-OD in the published literature. Similarly, olfactory response to CRS treatment is highly variable, with resolution of olfactory disturbance after standard therapies occurring in approximately 40% of refractory CRS patients [9].

Olfactory dysfunction in CRS is potentially complex and the interplay among possible mechanisms is poorly understood. The simple model of conductive loss due to impaired odorant transport to the olfactory cleft in CRS may explain a portion of the disease for some patients. Local and systemic inflammation likely contribute to varying degrees in particular individuals, with underlying factors such as age and presence of comorbid diabetes influencing the capacity for olfactory sensory neuron regeneration. Given the intricate and multifactorial nature of CRS-OD, compounded by inherent challenges of human cohort studies, it is no surprise that putative predictors and their relative importance have been inconsistently characterized across studies. Existing single-institution studies carry a significant risk of sampling bias and their use of univariate regression models are insufficient to identify predictor variables for CRS-OD. These analyses cannot account for all possible predictor variables or interactions among variables, and therefore, may offer limited insights. Additional attempts at categorizing outcomes with multivariable regression approaches that were not developed for predictive performance, or assessed as such, cannot be relied upon [10].

Traditional statistical approaches can model how system variables relate to one another and generate corresponding mathematical metrics of statistical significance. However, novel data analytics approaches including machine learning (ML) methods have shown improved classification accuracy and can be utilized to predict future outcomes, rather than focusing on individual components within a system. ML approaches are particularly useful when there is a role for including complex interactions that may otherwise be ignored or dismissed as noise when using traditional statistics [11], such as in the case of CRS-OD.

Understanding the heterogeneity of CRS-OD and interpreting multi-dimensional risk factors for outcomes prediction is foundational for future clinical care and research. The objective of this study was to test different ML-based predictive analytics approaches against traditional regression modeling for classification accuracy of OD in CRS patients. A secondary goal was to

112   explore top predictors in high-performing models to identify common predictor variables of
113   importance that may help explain the heterogeneity of OD found among CRS patients.
114
115   **MATERIALS and METHODS**
116   *Study Population*
117   Adult patients (≥18 years old) were recruited into a prospective, multi-center,
observational cohort study, for which multiple reports have been previously published [12-15].
All study patients were diagnosed with medically refractory CRS as defined by the American
Academy of Otolaryngology-Head and Neck Surgery 2007 guidelines [4]. Performance sites
consisted of tertiary care sinus centers located within academic hospital systems in North
America including: Oregon Health & Science University (OHSU; Portland, OR; eIRB#7198),
Stanford University (Palo Alto, CA; IRB#4947), and the Medical University of South Carolina
(Charleston, SC; IRB#12409), with central study coordination at OHSU. The Institutional
Review Board (IRB) at each performance site governed all study protocols, informed consent
documentation, and data safety monitoring.
127   At original study enrollment, participants were screened for demographics, social and
medical history (**Table 1**). The diagnoses of asthma, allergy, and aspirin-exacerbated respiratory
disease (AERD) were made by evaluation of the medical record, presence of classic symptoms
and self-report of prior testing. Subjects with comorbid cystic fibrosis, ciliary dyskinesia, or
autoimmune disease were included in the analysis. Patient reported outcome measures (PROMs)
were collected during study enrollment, but were not used in the predictive analytics given the
overlap between particular symptom ratings and objective smell loss [22-25].
134
135   *Objective Measures of Disease Severity*
136   Diagnostic measures of disease severity were collected as standard of care, and were also
137   used for investigational purposes. These well-established objective measures have been
138   recommended for clinical study [16], and include Lund-Kennedy nasal endoscopy scoring [17]
139   and high-resolution CT imaging graded using the Lund-Mackay scoring system [18].
140   The main outcome of interest in the current study is olfactory dysfunction as measured by
141   psychophysical testing. Olfactory function was assessed using the brief Smell Identification Test
142   (bSIT) in the years 2011-2013, and the 40-item Smell Identification Test (SIT) in the years 2013-
143   2015 (Sensonics Inc., Haddon Heights, NJ). Higher SIT total scores reflect a better sense of
144   smell, and categorical ratings of "smell loss" (anosmia + hyposmia) and "normosmia" were
145   assigned based on established scales [19-21].
147
148   *Data Management and Statistical Analyses*
149   Protected health information was previously removed, and study data were safeguarded
150   using a unique study identification number assignment for each participant. Study data were
151   securely transferred from a HIPAA compliant, relational database (Access, Microsoft Corp,
152   Redmond, WA.) to the University of Colorado Department of Otolaryngology-Head and Neck
153   Surgery password protected research server, according to specifications of a Data Use
154   Agreement between OHSU and the University of Colorado.
155   Study data were evaluated descriptively using count (%) for categorical variables and
median and interquartile range (IQR; 25th quantile, 75th quantile) for numeric variables.
Comparing variables between normosmics and those with smell loss, Fisher's exact test was used
for categorical variables and Wilcoxon rank sum test was used for numeric variables. Both the

original p-values and Benjamini-Hochberg multiple testing adjusted p-values ("q-values") were
reported [26]. Statistical comparisons with q-values < 0.05 were regarded as statistically
significant. All statistical and data analyses were completed using the R software program [27].
Machine learning models were compared to simpler logistic regression model with backwards
step-wise variable selection using Akaike information criteria (AIC). The step-wise variable
selection was re-performed during each iteration of the cross-validation procedure (details later),
in order to prevent biased estimates of classification accuracy [28].
166
Machine Learning Approaches to Classification
Four different machine learning predictive analytics models were applied, in order to
compare classification accuracy to logistic regression. All classifiers were fit using the caret R
package [29], which provides a unified framework for tuning and evaluating classification
accuracy. *Random forests (RF)* was chosen as it allows for non-linear and interaction effects;
conditional inference trees were used with permutation-based variable importance scores for
unbiased variable selection [30]. Similar to traditional logistic regression, least absolute
shrinkage and selection operator (*LASSO*) assumes only linear and additive affects (without
interaction) where regression coefficients are shrunk toward zero to perform variable selection
[31,32]. In this model, unimportant variables are given coefficients equal to zero, effectively
removing them from the model. Along these lines, multivariate adaptive regression splines
(*MARS*) was also applied in a similar fashion to traditional logistic regression, but it uses
stepwise methods for variable selection and allows for nonlinear and interaction effects [33].
Lastly, the *Support Vector Machine* (*SVM*) approach was applied with a radial basis kernel,
which allows for non-linear and interaction effects [34].
Repeated 10-fold cross validation (repeated 5 times [35]) was used to tune and internally
validate the classification accuracy of each model. The following measures of accuracy were
considered: area under receiver operating characteristic curve (AUC), sensitivity (proportion of
subjects with olfactory dysfunction that were correctly classified), and specificity (proportion of
subjects without olfactory dysfunction that were correctly classified). Both sensitivity and
specificity used a probability cutoff of 0.50. Pairwise two-sample t-tests were used to compare
cross-validation accuracy measures between models using the Benjamini-Hochberg method to
adjust for multiple testing. To deal with the fact that the two classes are unbalanced (dysosmia vs
normosmia), under-sampling was used within the cross-validation procedure, as implemented in
the caret R package [29,36]. Over-sampling was also considered, but produced nearly equal
classification accuracy in terms of AUC (results not shown). The method of "surrogate splits"
[37] was used to handle missing values in RF. The missForest R package [38] was used to
impute missing values for all other models, while excluding the outcome in order to prevent
over-fitting.
To identify the important predictor variables included in each classification algorithm,
permutation-based variable importance scores were used to rank variables from most to least
important in RF, while the absolute value of the standardized regression coefficient was used for
LASSO. The IML R package [39] was used to calculate variable importance scores for SVM
using a permutation method. All variable importance scores were scaled from 0 to 100, where
the most important variable for the model has a score of 100. Of note, for a categorical variable
with more than two categories, RF and LASSO calculate separate variable importance scores for
each category, whereas the approach used for SVM only calculates an overall score.
204

RESULTS

Final Cohort Characteristics

A total of 611 study participants met all inclusion criteria and were prospectively enrolled between April 2011 and July 2015. Demographics and comorbid disease characteristics, examined by olfactory classification, are described in **Table 1**. The overall median age for the final cohort was 51 years (IQR= 38.3, 61.7) years with slight female preponderance (53% female). Approximately one-third of the cohort exhibited nasal polyps (35%).

Study participants were stratified by olfactory testing category. Statistically significant differences (q<0.05) were observed between the normosmic and hyposmic cohorts in terms of objective disease measures (CT and endoscopy scores), age, sex, previous surgery, socioeconomic status, corticosteroid dependence, asthma/COPD, and AERD. Sinonasal conditions including nasal polyps, allergic fungal rhinosinusitis, and deviated septum were also significant factors.

Smell loss vs Normosmia Classification Accuracy

A logistic regression model for classification of baseline olfactory dysfunction demonstrated acceptable accuracy in the context of CRS (AUC 0.707). Three of the four machine learning models outperformed the traditional logistic regression model (**Table 2**). The SVM approach was the most accurate, with a relatively good classification accuracy (AUC 0.754) and much higher sensitivity than other the methods. LASSO and Random Forest also outperformed logistic regression, whereas MARS had the lowest AUC. **Figure 1** illustrates two-sample t-tests to compare measures of classification accuracy between all models (across the 50 cross-validation resampling estimates), using the Benjamini-Hochberg method to adjust for multiple testing. Note that SVM, RF and LASSO did not have significantly different mean AUC, but they had significantly higher mean AUC compared to logistic regression and MARS. SVM had significantly higher sensitivity compared to all other models. Specificity did not significantly differ between models, although SVM did have the lowest mean specificity.

Machine Learning Predictions: Top variables

ML algorithms are adept are recognizing patterns within complex data, but the lack of *a priori* framework results in the inability to understand *why* the algorithm made its decisions. The ML models each arrived at somewhat different relative importance of a given predictor variable. SVM, the model with the largest AUC, considered many variables to be influential, with 20 variables having variable importance scores >25 (**Fig 2**). In Random Forest and LASSO models, fewer variables were important and the most weight was placed on the presence of nasal polyps and the nasal endoscopy severity score (**Fig 3 and Suppl Fig 1**).

Top predictors across the approaches include corticosteroid dependence, prior surgery, nasal polyps, AERD, age, sex, and smoking history. Inflammatory disease severity, as measured by CT and nasal endoscopy scores, were also strong predictors of CRS-OD.

Socioeconomic factors such as insurance status, household income, and race are among top predictors across the three models displayed. Age was a less important variable in all models. Comorbid medical conditions including asthma, diabetes, septal deviation, alcohol use, and sleep apnea, are also of moderate importance. Although the presence of nasal polyps, asthma, and AERD, are significantly associated with CRS-OD, the presence of allergic rhinitis by history or by skin testing appear to carry relatively minimal weight in the CRS-OD classifications.

DISCUSSION

CRS is a heterogeneous process in terms of presentation, subtypes, natural history and response to treatments [2]. Current data from a multi-institutional CRS cohort studying olfactory loss in CRS with a sensitive olfactory test (Sniffin' Sticks) demonstrates that nearly 70% of the CRS population has significant olfactory loss, with 20% exhibiting complete anosmia [7]. The pathophysiology of OD in CRS is ascribed to both sensorineural and conductive effects of local tissue inflammation, on top of the myriad factors that can affect olfaction in the general population [1,40]. In previous studies, factors associated with worse baseline olfactory function in CRS patients included nasal polyposis, asthma, age, smoking, and eosinophilia [41]. Other works have shown CRS-OD response treatment in ~40% of patients, with risk factors such as olfactory dysfunction severity, nasal polyps, female gender, high socioeconomic status and non-smoking associating with better quality of life results. In multivariate regression, only nasal polyps and degree of baseline olfactory dysfunction maintained statistical significance, highlighting the need for robust sample size and analytical methods to glean useful information from human study [10].

Here, we utilized ML-based data science approaches to interrogate whether novel predictive analytics approaches could outperform a traditional statistical method of logistic regression in CRS-OD classification. Top predictors across the approaches contain many variables associated with olfactory function in previous studies, including, nasal polyps, prior surgery, AERD, age, sex, corticosteroid dependence, and smoking history. Inflammatory disease severity, as measured by CT and nasal endoscopy scores, are not surprisingly very important predictors of CRS-OD. Socioeconomic factors such as insurance status, household income, and race were among the important variables across the three top performing models. Since age was less important in all models, insurance status appears to be an independent predictor (i.e., Medicare insurance is not simply a proxy for advanced age). Comorbid medical conditions including asthma, diabetes, septal deviation, alcohol use, and sleep apnea, are also of moderate importance. Notably, these factors can be influenced by medical care and lifestyle modification, suggesting that other approaches to improve general health and well-being may be considered as part of a holistic approach to CRS-OD management. Although the presence of nasal polyps, asthma, and AERD, are significantly associated with CRS-OD here and in prior literature, the presence of allergic rhinitis by history or by skin testing appeared to carry relatively minimal weight in the CRS-OD classifications. This observation suggests that medical therapies for atopic diseases--including immunotherapy and targeted biologics--may not necessarily provide benefit for olfactory function in CRS.

We observed improved prediction accuracy with most ML approaches, as measured by AUC and sensitivity/specificity. ML is defined as the use of algorithms to break down data, learn from it, and then make a determination or prediction about some aspect. Whereas traditional statistical methods focus on modeling how system variables relate to one another and what statistical inference (e.g. significance in p-values) can be made, the goal of machine learning (ML) is not interpretation of individual components but prediction of future outcomes. In doing so, ML provides a novel approach to uncover previously unrecognized patterns among CRS-OD patients and thereby offers numerous advantages over regression analyses, which have been traditionally employed in studies of CRS disease severity and outcomes [42].

In this study, four different supervised ML algorithms were used map features of interest to the outcome or "label" of olfactory loss, and three outperformed traditional regression. In particular, the SVM model had improved accuracy that was driven largely by improved

sensitivity. The improved classification accuracy may be attributed to the ability of these ML
models to handle high-dimensional data in which more features exist than observations, and
include non-linear and interaction effects. In contrast, traditional statistical modeling with a large
number of potential features requires some form of dimension reduction or variable selection,
and exploration of interactions and non-linear effects is challenging with more than a small
number of predictors. As a result, we believe that ML and artificial intelligence data analytics are
well-suited to prime research and eventually for the application of precision medicine in
olfactory disorders, given the idiosyncrasies, nuances, and numerous possible predictor variables.
There are some limitations of the current study that should be addressed with regard to
ML. Adequate enrollment by sex and race are common sampling issues in healthcare ML
[43,44]. Details of this cohort have been extensively published and include even distributions by
age and sex. Racial/ethnic minorities and low socioeconomic status groups are underrepresented
perhaps as a function of geography and referral patterns of the enrollment sites, but also result
from the general lack of accessible and affordable healthcare and racial disparities inherent
within the U.S. healthcare system [45]. A related concern is that models created from our cohort
data may "overfit" when new or unseen clinical data are applied. Certainly, these approaches
should be further validated in independent studies, but nonetheless demonstrate the utility of data
science approaches to uncover patterns within expansive human data in a noisy disease process.
To incorporate a large enough patient dataset across three sites over several years of prospective
data collection, psychophysical testing included classification of smell loss by either SIT or
bSIT. Although the SIT may be more sensitive despite both of these tests being extensively
validated in the literature, our prior analysis in a CRS cohort has demonstrated excellent
diagnostic accuracy of the bSIT (AUC=0.873; 95% CI: 0.819, 0.927) [21]. Additionally, there
may be important data inputs (i.e., molecular endotyping data) that are not yet clinically
available. Serum markers, such as peripheral eosinophilia and serum IgE, have been proposed for
CRS in the past but have generally been disappointing and do not appear to correlate with tissue
levels [46,47]. Some of the clinical data input fields may associate phenotypes with likely
molecular endotypes, but such overlap is not universal [5]. Future goals include testing whether
additional accuracy is gained with the addition of molecular based biomarkers to the input data.
326
CONCLUSION
Here we demonstrate the importance of novel predictive analytics approaches in the study
of clinical olfactory disorders. Founded in data science principles rather than traditional statistics,
ML models generally outperformed logistic regression. Consistently observed predictors across
models include a weighted interest in socioeconomic status, and other potentially modifiable
conditions such as asthma/AERD. Further studies will be important to reproduce and validate
these findings, and might explore why certain novel predictor variables appear to be important.
Such approaches may have value for both clinical counseling and guidance for future basic
science and translational research.
336

ACKNOWLEDGMENTS
The authors would like to thank Drs. Miranda Kroehl, PhD, John Rice, PhD, and Krithika
Suresh, PhD, for biostatistical expertise in machine learning and prediction models. We would
also like to thank Drs. Peter Hwang, MD, Rod Schlosser, MD, and Luke Rudmik, MD, for their
contributions in original study enrollment and ongoing collaboration.

REFERENCES

1. Hummel T, Whitcroft KL, Andrews P et al. Position Paper on Olfactory Dysfunction.
Rhinology 2016 31;56(1):1-30.

2. Orlandi RR, Kingdom TT, Hwang PH, et al. International Consensus Statement on Allergy
and Rhinology: Rhinosinusitis. Int Forum Allergy Rhinol. 2016;6 Suppl 1:S22-209. Section X.B.

3. Fokkens WJ, Lund VJ, Mullol J, et al. European position paper on rhinosinusitis and nasal
polyps 2012. Rhinol. Suppl 2012;23: 1-298.

4. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update):
adult sinusitis. Otolaryngol Head Neck Surg. 2015;152(2 Suppl):S1-39.

5. Akdis CA, Bachert C, Cingi C, et al. Endotypes and phenotypes of chronic rhinosinusitis: a
PRACTALL document of the European Academy of Allergy and Clinical Immunology and the
American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol
2013;131(6):1479-90.

6. Soler ZM, Kohli P, Storck KA, Schlosser RJ. Olfactory Impairment in Chronic Rhinosinusitis
Using Threshold, Discrimination, and Identification Scores. Chem Senses 2016;41(9):713-719.

7. Schlosser RJ, Smith TL, Mace JC, et al. Factors driving olfactory loss in patients with chronic
rhinosinusitis: a case control study. Int Forum Allergy Rhinol 2020;10(1):7-14.

8. Kohli P, Naik AN, Harruff EE, et al. The prevalence of olfactory dysfunction in chronic
rhinosinusitis. Laryngoscope 2017; 127(2):309-320.

9. DeConde AS, Mace JC, Alt JA, Schlosser RJ, Smith TL, Soler ZM. Comparative effectiveness
of medical and surgical therapy on olfaction in chronic rhinosinusitis: a prospective, multi-
institutional study. Int Forum Allergy Rhinol. 2014;4(9):725-33.

10. Katotomichelakis M, Simopolous E, Tripsianis G, et al. Predictors of quality of life
outcomes in chronic rhinosinusitis after sinus surgery. Eur Arch Otorhinolaryngol 2014;
271(4):733-41.

11. Bzdok D, Altman N, Krzywinski M. Statistics versus machine learning. Nat Methods
2018;15(4):233-234.

12. Smith TL, Kern R, Palmer JN, et al. Medical therapy vs surgery for chronic rhinosinusitis: a
prospective, multi-institutional study with 1-year follow-up. Int Forum Allergy Rhinol
2013;3(1):4-9.

13. DeConde AS, Mace JC, Alt JA, et al. Longitudinal improvement and stability of the SNOT-
22 survey in the evaluation of surgical management for chronic rhinosinusitis. Int Forum Allergy
Rhinol. 2015; 5(3):233-239.

14. Soler ZM, Smith TL, Alt JA, et al. Olfactory-specific quality of life outcomes after
endoscopic sinus surgery. Int Forum Allergy Rhinol. 2016; 6(4): 407-413.

15. Ramakrishnan VR, Mace JC, Soler ZM, Smith TL. Examination of high-antibiotic users in a
multi-institutional cohort of chronic rhinosinusitis patients. Int Forum Allergy Rhinol.
2017;7(4):343-51.

16. Hopkins C, Hettige R, Soni-Jaiswal A, et al. Chronic rhinosinusitis outcome measures
(CHROME), developing a core outcome set for trials of interventions in chronic rhinosinusitis.
Rhinology 2018;56(1):22-32.

17. Lund VJ and Kennedy DW. Quantification for staging sinusitis. The Staging and Therapy
Group. Ann Otol Rhinol Laryngol Suppl. 1995;167:17-21.

18. Lund VJ and Mackay IS. Staging in rhinosinusitis. Rhinology. 1992;31(4):183-4.

19. Doty RL. The Smell Identification Test Administration Manual. 3. Haddon Heights, NJ:
Sensonics, Inc; 1995.

20. Doty RL. The Brief Smell Identification Test Administration Manual. Haddon Heights, NJ:
Sensonics, Inc; 2001.

21. El Rassi E, Mace JC, Steele TO, et al. Sensitivity analysis and diagnostic accuracy of the
Brief Smell Identification Test in patients with rhinosinusitis. Int Forum Allergy Rhinol.
2016;6(3):287-92.

22. Piccirillo JF, Merritt MG, Jr, Richards ML. Psychometric and clinimetric validity of the 20-
Item Sino-Nasal Outcome Test (SNOT-20) Otolaryngol Head Neck Surg. 2002;126(1):41–47.

23. Hopkins C, Gillett S, Slack R, et al. Psychometric validity of the 22-item Sinonasal Outcome
Test. Clin Otolaryngol. 2009;34(5):447–454.

24. Senior BA, Glaze C, Benninger MS. Use of the rhinosinusitis disability index (RSDI) in
rhinologic disease. Am J Rhinol. 2001; 15(1):15-20

25. Simopoulos E, Katotomichelakis M, Gouveris H, Tripsianis G, Livaditis M, Danielides V.
Olfaction-associated quality of life in chronic rhinosinusitis: adaptation and validation of an
olfaction-specific questionnaire. Laryngoscope 2012;122:1450–1454.

26. Benjamini Y and Hochberg Y. Controlling the false discovery rate: a practical and powerful
approach to multiple testing. Journal of the Royal statistical society: series B (Methodological)
1995;57(1):289-300.

27. R Core Team. 2019. R: A Language and Environment for Statistical Computing. Vienna,
Austria: R Foundation for Statistical Computing.

28. Hastie T, Tibshirani R, and Friedman J. The wrong and right way to do cross-
validation. Elements of Statistical Learning, Data Mining, Inference, Prediction, Springer, NY
2009: 245-247.

29. Kuhn, M. Building predictive models in R using the caret package. Journal of statistical
software 2008; 28(5):1-26.

30. Strobl C, Boulesteix AL, Zeileis A, Hothorn T. Bias in random forest variable importance
measures: Illustrations, sources and a solution. BMC bioinformatics 2007;8(1):25.

31. Tibshirani R. Regression shrinkage and selection via the lasso. Journal of the Royal
Statistical Society: Series B (Methodological) 1996;58(1):267-288.
417
32. Friedman J, Hastie T, and Tibshirani R. Regularization paths for generalized linear models
via coordinate descent. Journal of statistical software 2010;33(1):1.

33. Friedman JH. Multivariate adaptive regression splines. Annals of Statistics 1991;1-67.

34. Cristianini N and Shawe-Taylor J. An introduction to support vector machines and other
kernel-based learning methods. Cambridge university press, 2000.

35. Kim JH. Estimating classification error rate: Repeated cross-validation, repeated hold-out
and bootstrap. Computational statistics & data analysis 2009;53(11):3735-3745.

36. He H and Garcia EA. Learning from imbalanced data. IEEE Transactions on knowledge and
data engineering 2009;21(9):1263-1284.

37. Strobl C, Malley J, Tutz G. An introduction to recursive partitioning: Rationale, application,
and characteristics of classification and regression trees, bagging, and random forests.
Psychological methods 2009; 14:323.

38. Stekhoven DJ and Bühlmann, P. MissForest—non-parametric missing value imputation for
mixed-type data. Bioinformatics 2012;28(1):112-118.

39. Molnar C, Casalicchio G, Bischl B. iml: An R package for interpretable machine learning. J
Open Source Software 2018;3(26), 786.

40. Rombaux P, Huart C, Levie P, Cingi C, Hummel T. Olfaction in Chronic Rhinosinusitis.
Curr Allergy Asthma Rep 2016;16(5):41.

41. Litvack JR, Fong K, Mace J, et al. Predictors of olfactory dysfunction in patients with
chronic rhinosinusitis. Laryngoscope 2008;118:2225–30.

42. Michie D, Spiegelhalter D, Taylor C. Machine Learning, Neural, and Statistical
Classification. New York, NY: Ellis Horwood; 1994.

43. Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med
2019;380(14):1347-1358.

44. Cutillo CM, Sharma KR, Foschini L, et al; MI in Healthcare Workshop Working Group.
Machine intelligence in healthcare-perspectives on trustworthiness, explainability, usability, and
transparency. NPJ Digit Med 2020;3:47.

45. 2018 National Healthcare Quality and Disparities Report. Content last reviewed April 2020.
Agency for Healthcare Research and Quality, Rockville, MD.
https://www.ahrq.gov/research/findings/nhqrdr/nhqdr18/index.html

46. Gitomer SA, Fountain CR, Kingdom TT, et al. Clinical Examination of Tissue Eosinophilia
in Patients with Chronic Rhinosinusitis and Nasal Polyposis. Otolaryngol Head Neck Surg
2016;155(1):173-8.

47. Settipane GA. Nasal polyps and immunoglobulin E (IgE). Allergy Asthma Proc
1996;17(5):269-73.

Table 1. Study population. Collected demographics and clinical metadata used as inputs for classification models are shown here for the overall cohort, and those with and without olfactory dysfunction. Count (%) and Fisher's exact test were used for categorical variables, while median (25th quantile, 75th quantile) and Wilcoxon rank sum test were used for numeric variables. Data sorted from smallest to largest q-value (multiple testing adjusted p-value).

| Characteristic | Overall, n = 611 | n | Olfactory Dysfunction | | p-value | q-value |
			Yes, n = 203	No, n = 408		
CRS with POLYPS		611			**<0.001**	**<0.001**
No	399 (65%)		86 (42%)	313 (77%)		
Yes	212 (35%)		117 (58%)	95 (23%)		
TOTAL ENDOSCOPY SCORE	6.0 (4.0, 8.5)	607	8.0 (4.0, 11.0)	4.0 (2.0, 7.0)	**<0.001**	**<0.001**
TOTAL CT SCORE	12.0 (7.0, 16.0)	582	15.0 (10.0, 19.0)	11.0 (6.0, 14.0)	**<0.001**	**<0.001**
AERD		611			**<0.001**	**<0.001**
No	567 (93%)		173 (85%)	394 (97%)		
Yes	44 (7.2%)		30 (15%)	14 (3.4%)		
AGE	51.0 (38.3, 61.7)	611	56.6 (44.6, 65.4)	49.1 (36.9, 59.9)	**<0.001**	**<0.001**
PRIOR SURGERY		610			**<0.001**	**<0.001**
0	278 (46%)		66 (33%)	212 (52%)		
1	153 (25%)		56 (28%)	97 (24%)		
2	90 (15%)		34 (17%)	56 (14%)		
3	40 (6.6%)		24 (12%)	16 (3.9%)		
4+	49 (8.0%)		23 (11%)	26 (6.4%)		
INSURANCE		610			**<0.001**	**<0.001**
Employer provided	373 (61%)		112 (55%)	261 (64%)		
Medicaid	24 (3.9%)		4 (2.0%)	20 (4.9%)		
Medicare	129 (21%)		63 (31%)	66 (16%)		
None	6 (1.0%)		5 (2.5%)	1 (0.2%)		
Private	62 (10%)		13 (6.4%)	49 (12%)		
State Assisted	8 (1.3%)		4 (2.0%)	4 (1.0%)		
VA Benefits	3 (0.5%)		0 (0%)	3 (0.7%)		
VA Benefits / Tricare	5 (0.8%)		2 (1.0%)	3 (0.7%)		
ASTHMA		611			**<0.001**	**<0.001**
No	397 (65%)		110 (54%)	287 (70%)		
Yes	214 (35%)		93 (46%)	121 (30%)		

Characteristic	Overall, n = 611	n	Olfactory Dysfunction		p-value	q-value
			Yes, n = 203	No, n = 408		
SEPTAL DEVIATION		611			**<0.001**	**0.001**
No	408 (67%)		155 (76%)	253 (62%)		
Yes	203 (33%)		48 (24%)	155 (38%)		
RECURRENT ACUTE SINUSITIS		611			**<0.001**	**0.003**
No	571 (93%)		199 (98%)	372 (91%)		
Yes	40 (6.5%)		4 (2.0%)	36 (8.8%)		
STEROID DEPENDENCE		611			**0.003**	**0.009**
No	555 (91%)		174 (86%)	381 (93%)		
Yes	56 (9.2%)		29 (14%)	27 (6.6%)		
SEX		611			**0.013**	**0.037**
Female	324 (53%)		93 (46%)	231 (57%)		
Male	287 (47%)		110 (54%)	177 (43%)		
AFRS		611			**0.019**	**0.049**
No	593 (97%)		192 (95%)	401 (98%)		
Yes	18 (2.9%)		11 (5.4%)	7 (1.7%)		
COPD		611			**0.020**	**0.049**
No	579 (95%)		186 (92%)	393 (96%)		
Yes	32 (5.2%)		17 (8.4%)	15 (3.7%)		
HOUSEHOLD INCOME		595			**0.027**	0.064
0-25000	96 (16%)		34 (17%)	62 (16%)		
26000-50000	102 (17%)		47 (24%)	55 (14%)		
51000-75000	120 (20%)		37 (19%)	83 (21%)		
76000-100000	107 (18%)		28 (14%)	79 (20%)		
100000+	170 (29%)		51 (26%)	119 (30%)		
Inferior Turbinate Hypertrophy		611			0.091	0.200
No	520 (85%)		180 (89%)	340 (83%)		
Yes	91 (15%)		23 (11%)	68 (17%)		
CF or ciliary dysfunction		611			0.117	0.241
No	588 (96%)		199 (98%)	389 (95%)		
Yes	23 (3.8%)		4 (2.0%)	19 (4.7%)		
ALLERGY by HISTORY		611			0.143	0.277
No	480 (79%)		152 (75%)	328 (80%)		

Characteristic	Overall, n = 611	n	Olfactory Dysfunction		p-value	q-value
			Yes, n = 203	No, n = 408		
Yes	131 (21%)		51 (25%)	80 (20%)		
SITE		611			0.189	0.349
#1	222 (36%)		84 (41%)	138 (34%)		
#2	253 (41%)		77 (38%)	176 (43%)		
#3	136 (22%)		42 (21%)	94 (23%)		
OSA by HISTORY		611			0.215	0.376
No	584 (96%)		191 (94%)	393 (96%)		
Yes	27 (4.4%)		12 (5.9%)	15 (3.7%)		
EDUCATION (Yrs)	16.0 (13.0, 17.0)	608	15.0 (13.0, 16.0)	16.0 (13.0, 17.0)	0.235	0.392
RACE		610			0.247	0.393
African American	49 (8.0%)		18 (8.9%)	31 (7.6%)		
American Indian/Alaska Native	5 (0.8%)		2 (1.0%)	3 (0.7%)		
Asian	24 (3.9%)		10 (4.9%)	14 (3.4%)		
Native Hawaiian/Pacific Islander	1 (0.2%)		1 (0.5%)	0 (0%)		
Other	25 (4.1%)		12 (5.9%)	13 (3.2%)		
White	506 (83%)		160 (79%)	346 (85%)		
GERD		611			0.303	0.460
No	570 (93%)		186 (92%)	384 (94%)		
Yes	41 (6.7%)		17 (8.4%)	24 (5.9%)		
ETHNICITY		611			0.352	0.493
Hispanic / Latino	21 (3.4%)		9 (4.4%)	12 (2.9%)		
Non-Hispanic / Latino	590 (97%)		194 (96%)	396 (97%)		
ALCOHOL Use		608			0.344	0.493
No	313 (51%)		109 (54%)	204 (50%)		
Yes	295 (49%)		92 (46%)	203 (50%)		
ALLERGY_TESTING		611			0.382	0.510
No	362 (59%)		115 (57%)	247 (61%)		
Yes	249 (41%)		88 (43%)	161 (39%)		
DEPRESSION		611			0.403	0.510
No	518 (85%)		176 (87%)	342 (84%)		
Yes	93 (15%)		27 (13%)	66 (16%)		

Characteristic	Overall, n = 611	n	Olfactory Dysfunction		p-value	q-value
			Yes, n = 203	No, n = 408		
FIBROMYALGIA		611			0.408	0.510
No	584 (96%)		192 (95%)	392 (96%)		
Yes	27 (4.4%)		11 (5.4%)	16 (3.9%)		
OSA BY TESTING		611			0.450	0.543
No	557 (91%)		188 (93%)	369 (90%)		
Yes	54 (8.8%)		15 (7.4%)	39 (9.6%)		
ALCOHOL USE (#)	0.0 (0.0, 36.0)	608	0.0 (0.0, 24.0)	0.0 (0.0, 36.0)	0.473	0.552
DIABETES		609			0.536	0.605
No	558 (92%)		183 (91%)	375 (92%)		
Yes	51 (8.4%)		19 (9.4%)	32 (7.9%)		
AUTOIMMUNE DISEASE		610			0.589	0.645
No	573 (94%)		188 (93%)	385 (94%)		
Yes	37 (6.1%)		14 (6.9%)	23 (5.6%)		
IMMUNODEFICIENCY		611			0.626	0.664
No	592 (97%)		198 (98%)	394 (97%)		
Yes	19 (3.1%)		5 (2.5%)	14 (3.4%)		
SMOKER (current or former)		607			1.000	1.000
No	574 (95%)		190 (95%)	384 (95%)		
Yes	33 (5.4%)		11 (5.5%)	22 (5.4%)		

459
460
461
462

462 **Table 2**. **Comparing classification accuracy.** Three ML approaches outperform traditional
463 logistic regression. *AUC = area under receiver operating characteristic curve; SVM-Radial =*
464 *support vector machine with a radial basis kernel; Log Reg-Step = logistic regression with step-*
465 *wise variable selection.*
466
467
468

Model	AUC	Sensitivity	Specificity
SVM-Radial	0.754	0.726	0.665
Random Forest	0.744	0.649	0.696
LASSO	0.737	0.659	0.689
Log Reg-Step	0.707	0.635	0.676
MARS	0.682	0.604	0.667

469
470
471
472

Figure 1. Comparing classification accuracy between methods. Dots correspond to the mean
estimate (across all 50 cross-validation resampling estimates) and error bars are 95% confidence
intervals for the mean. Pairwise comparisons were performed using Welch's 2-sample t-test with
the Benjamini-Hochberg multiple testing adjusted p-values ("q-values"). Models with different
letters (a,b,c) have significantly different means ($q<0.05$), while models sharing the same letter
do not significantly differ ($q>0.05$). *SVM-Radial = support vector machine with a radial basis*
kernel; RF = random forest; Log Reg-Step = logistic regression with step-wise variable
selection.

Figure 2. **Variable importance display for most accurate classification model (Support**
Vector Machine with a radial basis kernel). Note the inclusion of many predictor variables –
32 are included with > 10% variable importance, suggesting potential interaction between
predictors. *SVM-Radial = support vector machine with a radial basis kernel.*
485

486
487
488
489

489 **Figure 3**. **Top 10 Predictors and Variable importance for Random Forest and LASSO**
490 **models.** *AERD = aspirin exacerbated respiratory disease; CF = cystic fibrosis.*
491

492
493

493   **Supplementary Figure 1**. **Complete list of predictors for Random Forest and LASSO**
494   **models.** Notably, the LASSO model incorporates significantly more features of interest than the
495   Random Forest algorithm (26 features with >10% importance in the prediction algorithm).
496
497